Dr Merchan on Key Data Supporting Pembrolizumab-Based Regimens in Advanced RCC

Jaime R. Merchán, MD, discusses the role of pembrolizumab plus axitinib or lenvatinib in previously untreated advanced renal cell carcinoma.

Related Keywords

Jaimer Merch , ,Division Of Medical Oncology ,Department Of Medicine ,Clinical Trials Program ,University Of Miami Health System ,Sylvester Comprehensive Cancer Center ,Clinical Oncology Research Program ,Medical Oncology ,Trials Program ,Miami Health System ,Cancers Symposium ,Advanced Rcc ,Pembrolizumab ,Axitinib ,Lenvatinib ,